Last reviewed · How we verify
NCT06747390: 856397
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Phase 1 trial testing Lidocaine 1% Injectable Solution in Oropharyngeal Squamous Cell Carcinoma (OPSCCA) in 30 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Ryan Carey |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 April 2025 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Lidocaine 1% Injectable Solution — full drug profile →
Conditions studied
- Oropharyngeal Squamous Cell Carcinoma (OPSCCA) — all drugs for Oropharyngeal Squamous Cell Carcinoma (OPSCCA) →
- Oropharyngeal Cancer — all drugs for Oropharyngeal Cancer →
- Human Papilloma Virus — all drugs for Human Papilloma Virus →
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
Sponsor
Ryan Carey
Who can join
18 and older, any sex, with Oropharyngeal Squamous Cell Carcinoma (OPSCCA) or Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on evidence that the local anesthetic lidocaine may have anticancer effects, this study will assess the safety and efficacy of intratumoral lidocaine injection at the time of direct laryngoscopy prior to TransOral Robotic Surgery (TORS) and neck dissection for oropharyngeal squamous cell carcinoma (OPSCC). The primary objective of the study is to determine if intratumoral lidocaine injection is safe and causes a major pathologic treatment effect in the primary tumor following surgical resection. The secondary objectives will be to determine if intratumoral lidocaine injection improves locoregional control rates, progression-free survival, metastasis-free survival, and overall survival compared to no injection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06747390
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lidocaine 1% Injectable Solution
Trials testing the same drug.
- NCT06546254 — 1% Lidocaine Paracervical Block for Endometrial Biopsy · NA · completed
- NCT06974019 — Empathy Through Pain Control: Buffered Compared to Unbuffered 1% Lidocaine During IUD Placement · NA · not yet recruiting
- NCT05364099 — Suprascapular Nerve Block for Treatment of Shoulder Pain in Individuals With Spinal Cord Injuries · Phase 4 · withdrawn
- NCT04750967 — Amitriptyline vs GON and SON Blocks in Migraine · NA · completed
- NCT04645823 — Spinal Fentanyl or Epidural Analgesia in the Early First Phase of Induced Labor · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747390 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ryan Carey
- Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747390.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing